Core Viewpoint - Heron Therapeutics won a court case against Fresenius Kabi USA regarding its Cinvanti product, affirming the validity of two patents related to the drug [2]. Company Summary - Heron Therapeutics (NASDAQ: HRTX) successfully defended its patents for Cinvanti in a U.S. District Court ruling [2]. - The court's decision is expected to protect Heron's market position and potentially enhance its revenue from Cinvanti, which is used for chemotherapy-induced nausea and vomiting [2]. Industry Context - The ruling may have implications for the broader biotech industry, particularly in the area of patent protections for pharmaceutical products [2]. - The outcome of this case could influence future litigation involving generic manufacturers and brand-name drug companies [2].

Core Viewpoint - The U.S. District Court for the District of Delaware ruled in favor of Heron Therapeutics in its patent litigation against Fresenius Kabi USA regarding the injectable emulsion CINVANTI® (aprepitant), affirming the validity of Heron's patents which expire in 2035 [1][2]. Group 1 - The court found that Fresenius' proposed generic product would infringe on Heron's U.S. Patent Nos. 9,561,229 and 9,974,794 [1][2]. - Heron plans to seek a court order to prevent Fresenius from launching its generic version of CINVANTI® until after the patents expire in 2035 [2]. - The litigation was initiated in July 2022 following Fresenius' submission of an Abbreviated New Drug Application to the FDA for a generic version of CINVANTI® [2]. Group 2 - Craig Collard, CEO of Heron, expressed satisfaction with the court's decision and emphasized the company's commitment to defending its patent estate [3]. - Heron Therapeutics is focused on developing and commercializing therapeutic innovations aimed at improving patient care, particularly in acute care and oncology [4].

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Melissa Jarel - Executive Director Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President & Chief Financial Officer William Forbes - Executive Vice President & Chief Development Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Serge Belanger - Needham Brandon Folkes - Rodman & Renshaw Operator Thank you for standing by and welcome to Her ...

For the quarter ended September 2024, Heron Therapeutics (HRTX) reported revenue of $32.81 million, up 4.4% over the same period last year. EPS came in at -$0.03, compared to -$0.17 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $36.4 million, representing a surprise of -9.86%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.03.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.04 per share when it actually produced a loss of $0.06, delivering a surprise of -50%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Heron Therapeutics, which ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other juris ...

Exhibit 99.1 Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance • Reported positive YTD 2024 Adjusted EBITDA of $1.4 million • Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million • ZYNRELEF ®(bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN") approved in September and on track for Q4 2024 launch • CMS Final Rule Non-Opioid Policy for Pain Relief includes ZYNRELEF as a qualifying product for separate payment ...

Core Insights - Heron Therapeutics reported a positive year-to-date 2024 Adjusted EBITDA of $1.4 million and expects Q4 2024 Net Revenue between $37 million and $43 million [1][2] - The company received FDA approval for the ZYNRELEF Vial Access Needle (VAN) in September 2024, with a planned launch in Q4 2024 [1][3] - ZYNRELEF has been included in the CMS Final Rule Non-Opioid Policy for Pain Relief, allowing for separate payment in specific healthcare settings [1][3] Financial Performance - For the three months ended September 30, 2024, Heron reported Net Product Sales of $32.8 million, compared to $31.4 million for the same period in 2023 [26] - The Gross Profit for the same period was $23.4 million, up from $13.2 million year-over-year [26] - The company reported a Net Loss of $4.8 million for the three months ended September 30, 2024, compared to a Net Loss of $25.0 million for the same period in 2023 [26] Product Sales Highlights - Acute Care Franchise Net Product Sales for the three and nine months ended September 30, 2024, were $7.4 million and $19.7 million, respectively, compared to $4.7 million and $12.9 million in 2023 [4] - ZYNRELEF Net Product Sales for the same periods were $6.3 million and $17.1 million, respectively, compared to $4.4 million and $12.0 million in 2023 [4] - APONVIE Net Product Sales for the three and nine months ended September 30, 2024, were $1.1 million and $2.6 million, respectively, compared to $0.3 million and $0.9 million in 2023 [5] Guidance and Future Outlook - The company has narrowed its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses, and Adjusted EBITDA, with updated ranges reflecting improved expectations [3] - The ZYNRELEF VAN is expected to simplify aseptic preparation and reduce withdrawal time significantly, enhancing its market potential [3] - ZYNRELEF will continue to receive separate payment under the CMS policy until at least the end of 2027, with a payment limitation set at $2,267.26 [3]

Wall Street analysts forecast that Heron Therapeutics (HRTX) will report quarterly loss of $0.03 per share in its upcoming release, pointing to a year-over-year increase of 82.4%. It is anticipated that revenues will amount to $36.4 million, exhibiting an increase of 15.8% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 25% to its current level. This demonstrates the covering analysts' collective reassessment of their initial pro ...

SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies.Mr. Kaseta currently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation, a bi ...